Analysis of colorectal cancers in British Bangladeshi identifies early onset, frequent mucinous histotype and a high prevalence of RBFOX1 deletion. by Sengupta, N, Yau, C, Sakthianandeswaren, A, Mouradov, D, Gibbs, P, Suraweera, N, Cazier, J, Polanco-Echeverry, G, Ghosh, A, Thaha, M, Ahmed, S, Feakins, R, Propper, D, Dorudi, S, Sieber, O, Silver, A, Lai, C

Genome analysis of colorectal cancers in British Bangladeshis identifies early onset and a high prevalence of rbfox1 deletion compared to Caucasians by Sengupta, N, Yau, C, Sakthianandeswaren, A, Mouradov, D, Gibbs, P, Suraweera, N, Cazier, J, Polanco-Echeverry, G, Ghosh, A, Thaha, M, Ahmed, S, Feakins, R, Propper, D, Dorudi, S, Sieber, O, Silver, A, Lai, C

Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance by Nijhuis, A, Thompson, H, Adam, J, Parker, A, Gammon, L, Lewis, A, Bundy, J, Soga, T, Jalaly, A, Propper, D, Jeffery, R, Suraweera, N, McDonald, S, Thaha, M, Feakins, R, Lowe, R, Bishop, C, Silver, A

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 M... by Adams, R, Meade, A, Seymour, M, Wilson, R, Madi, A, Fisher, D, Kenny, S, Kay, E, Hodgkinson, E, Pope, M, Rogers, P, Wasan, H, Falk, S, Gollins, S, Hickish, T, Bessell, E, Propper, D, Kennedy, M, Kaplan, R, Maughan, T

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial by Iveson, T, Kerr, R, Saunders, M, Cassidy, J, Hollander, N, Tabernero, J, Haydon, A, Glimelius, B, Harkin, A, Allan, K, McQueen, J, Scudder, C, Boyd, K, Briggs, A, Waterston, A, Medley, L, Wilson, C, Ellis, R, Essapen, S, Dhadda, A, Harrison, M, Falk, S, Raouf, S, Rees, C, Olesen, R, Propper, D, Bridgewater, J, Azzabi, A, Farrugia, D, Webb, A, Cunningham, D, Hickish, T, Weaver, A, Gollins, S, Wasan, H, Paul, J